ORYZON receives a new 1.14 M USD public grant to explore new indications for epigenetic inhibitors
MADRID, SPAIN and CAMBRIDGE MA.
• Within a consortium, led by Oryzon, that will have a 1.7 M USD aggregated budget
Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, has announced today the company has been granted a preferential 10 year-term loan with a three-year grace period at 0% interest by the Ministry of Science, Innovation and Universities, Government of Spain, and FEDER Funds from the European Union. Thanks to this loan, Oryzon will receive approximately 1.14 M USD (in multiyear disbursements) for further development of its epigenetic inhibitors in combination with other available drugs against oncologic indications.